VNRX•prnewswire•
Volition Issues Business Review 2025
Summary
HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief Executive Officer As 2025 draws to a close, I would like to...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 17, 2025 by prnewswire